Matt Kelmon
Matt Kelmon
call definitely deserved glad good
I'm glad it's over. It was definitely an overhang on the stock. I don't think NTP deserved anything but it was a good call to get it out of the way.
call deserved glad good
I'm glad it's over. I don't think NTP deserved anything, but it was a good call to get it out of the way.
february odds shut slim stock widows
I think the odds of it getting shut down are very, very slim at this point. As an investor, it's going to be a very, very choppy stock between now and February 24. It's not for widows and orphans. That being said, the stock is cheap. When the overhang's gone, the stock will go higher.
bottom company continued cost cutting earnings help markets money room worst
Continued cost cutting is going to help the bottom line. The company is making money in one of the worst markets and there's room for earnings to go a lot higher.
five next question stocks
There's no question that drug stocks are dirt-cheap but are they going to be dirt-cheap for the next five years?
looks spending
I am disappointed. It looks like they are doing a lot more spending than expected.
growth leverage might percent revenue seen top
The 30 percent revenue growth days, I think we might have just have seen them top out. Now they have to take what they've got and see how they can leverage it.
happens japan recovery
A recovery for Japan is inevitable, and when it happens it will be big for all of tech,
clicking demand great strong
Demand is very strong and it will be a great back-to-school season, especially for Intel. Semiconductors are really clicking on all cylinders.